The first candidate, CGEN-15001, has demonstrated therapeutic potential in multiple sclerosis and rheumatoid arthritis in in-vivo studies, and Compugen said it continues to move forward with that program and is in discussions with possible partners
The first candidate, CGEN-15001, has demonstrated therapeutic potential in multiple sclerosis and rheumatoid arthritis in in-vivo studies, and Compugen said it continues to move forward with that program and is in discussions with possible partners
Neovacs SA, of Paris, received a €1.4 million (US$2.1 million) payment from French innovation agency OSEO for the Tracker Project, which focuses on rheumatoid arthritis therapy
Neovacs SA, of Paris, received a €1.4 million (US$2.1 million) payment from French innovation agency OSEO for the Tracker Project, which focuses on rheumatoid arthritis therapy
Augurex Life Sciences Corp., of Vancouver, British Columbia, said data from a study showed the company's rheumatoid arthritis (RA) biomarker blood test could lead to earlier diagnosis of the disease
UCB SA, of Brussels, Belgium, reported data showing that the addition of Cimzia (certolizumab pegol) to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis patients
SuppreMol GmbH, of Martinsried, Germany, closed an agreement to in license an antibody directed against interleukin 3 (IL-3) developed by the Molecular Immunology research group at the University of Regensburg, where a team recently demonstrated that IL-3 played an important role in the onset of rheumatoid arthritis
Under the agreement, Pepscan, using its CLIPS technology, will work with Phylogica to optimize therapeutic Phylomer drug candidates against CD40-ligand for the treatment of rheumatoid arthritis, autoimmune diseases and inflammatory disorders...UCB SA, of Brussels, Belgium, reported results from a post-hoc analysis of the RAPID 1 study, which suggested that moderate to severe rheumatoid arthritis patients treated with pegylated anti-TNF drug Cimzia (certolizumab pegol), in combination with
Under the agreement, Pepscan, using its CLIPS technology, will work with Phylogica to optimize therapeutic Phylomer drug candidates against CD40-ligand for the treatment of rheumatoid arthritis, autoimmune diseases and inflammatory disorders
Rigel's lead program, oral Syk inhibitor fostamatinib, recently started a large Phase III program in rheumatoid arthritis led by partner AstraZeneca plc, of London. (See BioWorld Today, Jan. 21, 2005, and Sept. 30, 2010
Last year Actemra won FDA approval as a once-monthly intravenous treatment for moderately to severely active rheumatoid arthritis. (See BioWorld Today, Jan. 12, 2010
A panel of the court ruled that the patent relating to Centocor antitumor necrosis factor alpha rheumatoid arthritis treatments was invalid, the company said
The Cambridge, Mass.-based company will advance its pain and inflammation pipeline, including Synavive for rheumatoid arthritis, and seek additional research collaborations for its high throughput screening and ion channel platforms
Genentech Inc., of South San Francisco, a unit of the Roche Group, said the FDA extended the Actemra (tocilzumab) label to include inhibition and slowing of structural joint damage, improvement of physical function and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis when given in combination with methotrexate
The European Union awarded $7.6 million to a research consortium comprised of 4SC AG, of Planegg-Martinsried, Germany, Anaxomics Biotech, of Spain, and a number of European Universities for the purpose of investigating the link between periodontal disease and rheumatoid arthritis (RA
BioWorld International | Wednesday, December 29, 2010
The European Union awarded $7.6 million to a research consortium comprised of 4SC AG, of Planegg-Martinsried, Germany, Anaxomics Biotech, of Spain, and a number of European Universities for the purpose of investigating the link between periodontal disease and rheumatoid arthritis (RA
The first candidate, CGEN-15001, has demonstrated therapeutic potential in multiple sclerosis and rheumatoid arthritis in in-vivo studies, and Compugen said it continues to move forward with that program and is in discussions with possible partners